Loading...
Market
Story
Pfizer's Talzenna-Xtandi Combo Significantly Prolongs Survival in Final Phase 3 Prostate Cancer Study
Oct 10, 2024, 10:55 AM
Pfizer announced that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly extended overall survival in men with metastatic castration-resistant prostate cancer (mCRPC), according to the final prespecified overall survival analysis of the phase 3 TALAPRO-2 trial. The study demonstrated that the drug combination significantly prolonged patients' lives compared to enzalutamide alone, offering a promising new treatment option for this aggressive form of prostate cancer.
View original story
Similar markets
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Revuforj holds the largest market share • 25%
Revuforj holds the second largest market share • 25%
Revuforj holds the third largest market share • 25%
Revuforj holds less than third place in market share • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Leading • 25%
Second • 25%
Third • 25%
Lower • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%